This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Schaffer, A. Search for Related Content PubMed PubMed Citation Articles by Schaffer, A.

Insulin-like Growth Factor-I and Risk of High-Grade Cervical Intraepithelial Neoplasia

Departments of ¹ Epidemiology and Biostatistics, ² Oncology, and ³ Gynaecology and Obstetrics, McGill University; ⁴ Department of Social and Preventive Medicine, Université de Montréal; Departments of ⁵ Obstetrics and Gynecology and ⁶ Pathology, and ⁷ Lady Davis Research Institute, Sir Mortimer B. Davis-Jewish General Hospital; and Departments of ⁸ Microbiology and Infectious Diseases and ⁹ Gynaecology, Centre Hospitalier de l'Université de Montréal, Université de Montréal, Montréal, Québec, Canada

Requests for reprints: Eduardo Franco, Division of Cancer Epidemiology, McGill University, 546 Pine Avenue West, Montréal, Québec, Canada H2W 1S6. Phone: 514-398-6032; Fax: 514-398-5002. E-mail: eduardo.franco{at}mcgill.ca

Insulin-like growth factors (IGF) and their binding proteins (IGFBP) have been implicated in the risk of several epithelial or glandular tumors, including prostate cancer, breast cancer, and colon cancer. Cervical cancer, which is also of epithelial origin, has been shown to overexpress receptors for IGF-I, and plasma levels of IGF-I have been positively associated with cervical cancer precursors in one epidemiologic study. In this case-control study, we investigated plasma levels of IGF-I and IGFBP-3 in relation to the risk of histologically confirmed high-grade cervical intraepithelial neoplasia (HGCIN) and the risk of human papillomavirus (HPV) infection. Included in this analysis were 329 cases and 621 controls recruited from clinics affiliated with two Montréal-area hospital centers. We observed a reduced risk of HGCIN for increasing levels of IGF-I, with an adjusted odds ratio (OR) of 0.40 (95% confidence interval, 0.19-0.87) for the highest quartile relative to the lowest quartile of IGF-I. No association was observed between IGFBP-3 levels and HGCIN. Among controls, IGF-I was associated with a decreased risk of being positive for HPV-16 or HPV-18, with an adjusted odds ratio of 0.20 (95% confidence interval, 0.05-0.87) for the highest quartile relative to the lowest quartile of IGF-I. There was no association observed between IGFBP-3 levels and HPV infection status. IGF-I–mediated effects seemed to predominate among women <30 years of age. In contrast to the previously reported study, our results suggest that levels of IGF-I in young women may be inversely associated with HGCIN, a precursor to cervical cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(4):716–22)

This article has been cited by other articles:

				T. G. Harris, R. D. Burk, H. Yu, H. Minkoff, L. S. Massad, D. H. Watts, Y. Zhong, S. Gange, R. C. Kaplan, K. Anastos, et al. Insulin-Like Growth Factor Axis and Oncogenic Human Papillomavirus Natural History Cancer Epidemiol. Biomarkers Prev., January 1, 2008; 17(1): 245 - 248. [Abstract] [Full Text] [PDF]